Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
112.08
-2.66 (-2.32%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
92
93
Next >
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
October 22, 2023
The companies studied a combination of Keytruda and Padcev in bladder cancer patients.
Via
Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
October 22, 2023
From
Merck & Co., Inc.
Via
Business Wire
3 Safe Dividend Stocks to Beat Inflation
October 21, 2023
Higher prices make things tougher for consumers and companies alike. Some corporations, however, are capable of pushing through this headwind.
Via
The Motley Fool
Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
October 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Looking At Merck & Co's Recent Unusual Options Activity
October 19, 2023
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
October 19, 2023
Via
Benzinga
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
October 20, 2023
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon.
Via
Benzinga
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
October 20, 2023
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.
Via
Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
October 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck & Company Inc. (NYSE: MRK) Highlighted for Surprising Price Action
October 05, 2023
Via
Investor Brand Network
7 Healthcare Stocks to invest in for a Healthy Future
October 20, 2023
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners.
Via
InvestorPlace
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer
October 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
October 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
October 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
October 19, 2023
From
Daiichi Sankyo
Via
Business Wire
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...
Via
Benzinga
Exposures
Product Safety
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
October 17, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery
October 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Healthcare Portfolio Focus Stocks
October 16, 2023
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.
Via
Talk Markets
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
October 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need.
October 16, 2023
Merck has a slew of in-progress products in its pipeline and pays a decent dividend. So, consider shoring up your portfolio with MRK stock.
Via
InvestorPlace
7 Safe Stocks to Steady Your Portfolio in 2024
October 15, 2023
With circumstances in the market applying the jitters, concerned investors may want to play these safe stocks to buy.
Via
InvestorPlace
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
October 13, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients
October 10, 2023
Merck & Co Inc (NYSE: MRK) reported topline data from the Phase 3 KEYNOTE-671 trial investigating Keytruda, Merck's anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable...
Via
Benzinga
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
October 10, 2023
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging.
Via
Benzinga
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
October 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
October 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
October 09, 2023
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.
Via
Talk Markets
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’
October 09, 2023
These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
October 06, 2023
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth.
Via
MarketBeat
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
92
93
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.